ClinicalTrials.gg
CompletedNCT03500549Updated Mar 25, 2022Results posted

Study to Evaluate the Efficacy and Safety of APL-2 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

A Phase 3 interventional study of Pegcetacoplan and Soliris in Paroxysmal Nocturnal Hemoglobinuria, sponsored by Apellis Pharmaceuticals, Inc.. Completed at 53 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-25.

Sponsored by Apellis Pharmaceuticals, Inc. (part of Biogen) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 68 studies in Hemoglobinuria, Paroxysmal with a site in United States — 10 open to participants now, 16 under way, 4 of them phase 3. Hemoglobinuria, Paroxysmal · United States.

Enrollment
15th of 54
80 · median 53
Started
2018
with 3 others
Phase 3
22 of 68
1 open now
Registered
45th of 68
by date
Lead sponsor
3 of 68
Apellis Pharmaceuticals, Inc.

Among the 68 studies in Hemoglobinuria, Paroxysmal with a site in United States, this one is the 15th largest by enrollment of the 54 interventional ones that give a count, is one of 4 that started in 2018, is one of 22 in phase 3, and was the 45th registered.

Hemoglobinuria, Paroxysmal

191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.

Browse Hemoglobinuria, Paroxysmal studies →

Open to participants now

10 of the 68 studies in Hemoglobinuria, Paroxysmal with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 30 Hemoglobinuria, Paroxysmal studies recruiting now, 14 (47%) set no upper age limit and 12 (40%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 68 studies in Hemoglobinuria, Paroxysmal with a site in United States, or all of them as a file.
02

Study summary

Evaluation of the Efficacy and Safety of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria

03

Conditions studied

  • Paroxysmal Nocturnal Hemoglobinuria
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 18 years of age
  • Primary diagnosis of PNH confirmed by high-sensitivity flow cytometry
  • On treatment with eculizumab. Dose of eculizumab must have been stable for at least 3 months prior to the Screening Visit
  • \<10.5 g/dL at the Screening Visit
  • Absolute reticulocyte count > 1.0x at the Screening Visit
  • count of >50,000/mm3 at the Screening Visit
  • >500/mm3 at the Screening Visit
  • Vaccination against Neisseria meningitides types A, C, W, Y and B, Streptococcus pneumoniae and Haemophilus influenzae Type B (Hib) either within 2 years prior to Day 1 dosing, or within 14 days after starting treatment with APL-2. Unless documented evidence exists that subjects are non-responders to vaccination as evidenced by titers or display titer levels within acceptable local limits
  • Women of (WOCBP) must have a negative pregnancy test at the Screening and Day -28 Visit (Run-in Period) and must agree to use protocol defined methods of for the duration of the study and 90 days after their last dose of study drug
  • Males must agree to use protocol defined methods of contraception and agree to refrain from donating sperm for the duration of the study and 90 days after their last dose of study drug
  • Willing and able to give
  • Willing and able to self-administer APL-2 (administration by caregiver will be allowed)
  • Have a (BMI) ≤35.0 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Active bacterial infection that has not resolved within 14 week of Day -28 (first dose of APL-2)
  • Receiving iron, folic acid, vitamin B12 and EPO, unless the dose is stable, in the 4 weeks prior to Screening
  • Hereditary complement deficiency
  • History of bone marrow transplantation
  • History or presence of or idiosyncratic reaction to compounds related to the product or SC administration
  • Participation in any other investigational drug trial or exposure to other investigational agent within 30 days or 5 half-lives (whichever is longer)
  • Currently breast-feeding women
  • Inability to cooperate or any condition that, in the opinion of the investigator, could increase the subject's risk of participating in the study or confound the outcome of the study

This study includes cardiac safety evaluations. The following cardiac eligibility criteria are necessary to avoid confounding the cardiac safety outcomes:

  • History or family history of Long Syndrome or torsade de pointes, unexplained syncope, syncope from an uncorrected cardiac etiology, or family history of sudden death
  • Myocardial infarction, CABG, coronary or cerebral artery stenting and /or angioplasty, stroke, cardiac surgery, or hospitalization for congestive heart failure within 3 months or greater than Class 2 Angina Pectoris or Heart Failure Class >2
  • QTcF > 470 ms, PR > 280 ms
  • Mobitz II 2nd degree AV Block, 2:1 AV Block, High Grade AV Block, or Complete Heart Block unless the patient has an implanted pacemaker or implantable cardiac defibrillator (ICD) with backup pacing capabilities
  • Receiving Class 1 or Class 3 antiarrhythmic agents, or arsenic, methadone, ondansetron or pentamidine at screening
  • Receiving any other QTc-prolonging drugs (see Appendix 4 in Section 19.4), at a stable dose for less than 3 weeks prior to dosing
  • Receiving prophylactic ciprofloxacin, erythromycin or azithromycin for less than one week prior to the first dose of study medication (must have a repeat screening after one week of prophylactic antibiotics with QTcF \< 470 ms)
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    Pegcetacoplan

    1080 mg pegcetacoplan administered subcutaneously twice-weekly or every three days.

    Drug: Pegcetacoplan · Drug: Soliris

  • Active comparator
    Eculizumab

    Complement (C5) Inhibitor.

    Drug: Pegcetacoplan · Drug: Soliris

Interventions

06

What researchers measure

Primary outcomes

  1. Least Squares (LS) Mean Change From Baseline to Week 16 in Hemoglobin (Hb) Level During the RCP

    Baseline was the average of measurements recorded before taking the first dose of pegcetacoplan, which included local and central laboratory values during the screening period. Analysis excluded data before the RCP and was censored for transfusions.

    Time frame: Baseline and Week 16

Secondary outcomes

  1. Percentage of Subjects Who Did Not Require a Transfusion (Transfusion Avoidance) During the RCP

    Subjects who experienced more than 1 transfusion during the RCP are only counted once. Subjects who did not have a transfusion but withdrew before Week 16 were considered as having a transfusion in the analysis of transfusion avoidance.

    Time frame: Day 1 to Week 16

  2. LS Mean Change From Baseline to Week 16 in Absolute Reticulocyte Count (ARC) During the RCP

    Baseline was the average of available measurements recorded from central laboratory before taking the first dose of pegcetacoplan. Analysis excluded data before the RCP and was censored for transfusions.

    Time frame: Baseline and Week 16

  3. LS Mean Change From Baseline to Week 16 in Lactate Dehydrogenase (LDH) Level During the RCP

    Baseline was the average of available measurements recorded from central laboratory before taking the first dose of pegcetacoplan. Analysis excluded data before the RCP and was censored for transfusions.

    Time frame: Baseline and Week 16

  4. LS Mean Change From Baseline to Week 16 in Functional Assessment of Chronic Illness Therapy (FACIT) - Fatigue Scale Score During the RCP

    The FACIT-fatigue scale version 4 is a 13-item Likert scaled instrument where the subject was presented with 13 statements and asked to indicate their response as it applied to the past 7 days. The 5 possible responses were 'Not at all' (0), 'A little bit (1), 'Somewhat' (2), 'Quite a bit' (3) and 'Very much' (4). With 13 statements the total score had a range of 0 to 52. A higher score corresponds to a higher quality of life (QoL). Baseline was the last available, nonmissing observation before taking the first dose of pegcetacoplan. Data collected after transfusion is excluded from analysis.

    Time frame: Baseline and Week 16

  5. Percentage of Subjects Who Achieved a Hb Response in the Absence of Transfusions at Week 16

    Hb response was defined as an increase of at least 1 g/dL in Hb from Baseline at Week 16. Baseline was the average of measurements recorded before taking the first dose of pegcetacoplan, which included local and central laboratory values during the screening period. Analysis excluded data before the RCP and was censored for transfusions.

    Time frame: Baseline and Week 16

  6. Percentage of Subjects Who Achieved Reticulocyte Normalization in the Absence of Transfusions at Week 16

    Reticulocyte normalization was defined as the ARC being below the upper limit of the gender-specific normal range at Week 16, censored for transfusions. Subjects who received a transfusion between Day 1 and Week 16 or withdrew without providing efficacy data at Week 16 were classified as nonresponders.

    Time frame: Week 16

  7. Percentage of Subjects Who Achieved Hb Normalization in the Absence of Transfusions at Week 16

    Hb normalization was defined as the Hb level being above the lower limit of the normal range at Week 16, censored for transfusions. Subjects who received a transfusion between Day 1 and Week 16 or withdrew without providing efficacy data at Week 16 are classified as nonnormalization.

    Time frame: Week 16

  8. LS Mean Change From Baseline to Week 16 in Indirect Bilirubin Level During the RCP

    Baseline was the average of available measurements recorded from central laboratory before taking the first dose of pegcetacoplan. Analysis excluded data before the RCP and was censored for transfusions.

    Time frame: Baseline and Week 16

  9. LS Mean Change From Baseline to Week 16 in Haptoglobin Level During the RCP

    Baseline was the average of available measurements recorded from central laboratory before taking the first dose of pegcetacoplan. Analysis excluded data before the RCP and was censored for transfusions.

    Time frame: Baseline and Week 16

  10. LS Mean Change From Baseline to Week 16 in Linear Analog Scale Assessment (LASA) Scores During the RCP

    The LASA consists of 3 items, where the respondents were asked to rate their perceived level of functioning. Specific domains included activity level, ability to carry out daily activities, and an item for overall QoL. Their level of functioning was reported on a 0 to 100 scale with 0 indicates "As low as could be" and 100 indicates "As high as could be". The combined score ranged from 0 to 300, with higher scores corresponding to a higher QoL.

    Time frame: Baseline and Week 16

  11. LS Mean Change From Baseline to Week 16 in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Core 30 Scale (QLQ-C30) Scores During the RCP

    The EORTC QLQ-C30 questionnaire (version 3.0) consists of 30 questions comprised of both multi-item scales and single-item measures to assess overall QoL in subjects. Questions are designated by functional scales, symptom scales, and global subject QoL/overall perceived health status. For the first 28 questions the 4 possible responses are "Not at all' (1), 'A little' (2), 'Quite a bit' (3) and 'Very much' (4). For the remaining 2 questions the response is requested on a 7-point scale from 1 ('Very poor') to 7 ('Excellent'). The raw scale scores were linear transformed, producing scale scores that ranged from 0% to 100%. A high scale score represents a higher response level. Hence for the functional scales and the global health status a higher score indicates a better QoL, whilst for the symptom scale scores this is implied by a lower score.

    Time frame: Baseline and Week 16

  12. Total Number of PRBC Units Transfused During the RCP

    Subjects who withdrew during the RCP before Week 16 will have their number of units of PRBC estimated from the duration they were in the study.

    Time frame: Day 1 to Week 16

  13. Mean Change From Baseline to Week 48 in Hb Level During the Treatment Period

    Baseline was the average of measurements recorded before taking the first dose of pegcetacoplan, which included local and central laboratory values during the screening period. Analysis excluded data before the RCP and was censored for transfusions.

    Time frame: Baseline and Week 48

  14. Mean Change From Week 17 to Week 48 in Hb Level During the Open-label Period

    Baseline was the average of measurements recorded before taking the first dose of pegcetacoplan, which included local and central laboratory values during the screening period. Analysis excluded data before the RCP and was censored for transfusions.

    Time frame: Week 17 and Week 48

  15. Mean Change From Baseline to Week 48 in ARC During the Treatment Period

    Baseline was the average of available measurements recorded from central laboratory before taking the first dose of pegcetacoplan. Analysis excluded data before the RCP and was censored for transfusions.

    Time frame: Baseline and Week 48

  16. Mean Change From Week 17 to Week 48 in ARC During the Open-label Period

    Baseline was the average of available measurements recorded from central laboratory before taking the first dose of pegcetacoplan. Analysis excluded data before the RCP and was censored for transfusions.

    Time frame: Week 17 and Week 48

  17. Mean Change From Baseline to Week 48 in LDH Level During the Treatment Period

    Baseline was the average of available measurements recorded from central laboratory before taking the first dose of pegcetacoplan. Analysis excluded data before the RCP and was censored for transfusions.

    Time frame: Baseline and Week 48

  18. Mean Change From Week 17 to Week 48 in LDH Level During the Open-label Period

    Baseline was the average of available measurements recorded from central laboratory before taking the first dose of pegcetacoplan. Analysis excluded data before the RCP and was censored for transfusions.

    Time frame: Week 17 and Week 48

  19. Mean Change From Baseline to Week 48 in FACIT-Fatigue Scale Score During the Treatment Period

    The FACIT-fatigue scale version 4 is a 13-item Likert scaled instrument where the subject was presented with 13 statements and asked to indicate their response as it applied to the past 7 days. The 5 possible responses were 'Not at all' (0), 'A little bit (1), 'Somewhat' (2), 'Quite a bit' (3) and 'Very much' (4). With 13 statements the total score had a range of 0 to 52. A higher score corresponds to a higher QoL. Baseline was the last available, nonmissing observation before taking the first dose of pegcetacoplan. Data collected after transfusion is excluded from analysis.

    Time frame: Baseline and Week 48

  20. Mean Change From Week 17 to Week 48 in FACIT-Fatigue Scale Score During the Open-label Period

    The FACIT-fatigue scale is a 13 item Likert scaled instrument where the subject was presented with 13 statements and asked to indicate their response as it applied to the past 7 days. The 5 possible responses were 'Not at all' (0), 'A little bit (1), 'Somewhat' (2), 'Quite a bit' (3) and 'Very much' (4). With 13 statements the total score had a range of 0 to 52. Higher score corresponds to a higher QoL.

    Time frame: Week 17 and Week 48

  21. Mean Change From Baseline to Week 48 in LASA Scores During the Treatment Period

    The LASA consists of 3 items, where the respondents were asked to rate their perceived level of functioning. Specific domains included activity level, ability to carry out daily activities, and an item for overall QoL. Their level of functioning was reported on a 0 to 100 scale with 0 indicates "As low as could be" and 100 indicates "As high as could be". The combined score ranged from 0 to 300, with higher scores corresponding to a higher QoL.

    Time frame: Baseline and Week 48

  22. Mean Change From Week 17 to Week 48 in LASA Scores During the Open-label Period

    The FACIT-fatigue scale is a 13 item Likert scaled instrument where the subject was presented with 13 statements and asked to indicate their response as it applied to the past 7 days. The 5 possible responses were 'Not at all' (0), 'A little bit (1), 'Somewhat' (2), 'Quite a bit' (3) and 'Very much' (4). With 13 statements the total score had a range of 0 to 52. Higher score corresponds to a higher QoL.

    Time frame: Week 17 and Week 48

  23. Mean Change From Baseline to Week 48 in QLQ-C30 Scores During the Treatment Period

    The EORTC QLQ-C30 questionnaire (version 3.0) consists of 30 questions comprised of both multi-item scales and single-item measures to assess overall QoL in subjects. Questions are designated by functional scales, symptom scales, and global subject QoL/overall perceived health status. For the first 28 questions the 4 possible responses are 'Not at all' (1), 'A little' (2), 'Quite a bit' (3) and 'Very much' (4). For the remaining 2 questions the response is requested on a 7-point scale from 1 ('Very poor') to 7 ('Excellent'). The raw scale scores were linear transformed, producing scale scores that ranged from 0% to 100%. A high scale score represents a higher response level. Hence for the functional scales and the global health status a higher score indicates a better QoL, whilst for the symptom scale scores this is implied by a lower score.

    Time frame: Baseline and Week 48

  24. Mean Change From Week 17 to Week 48 in QLQ-C30 Scores During the Open-label Period

    The EORTC QLQ-C30 questionnaire (version 3.0) consists of 30 questions comprised of both multi-item scales and single-item measures to assess overall QoL in subjects. Questions are designated by functional scales, symptom scales, and global subject QoL/overall perceived health status. For the first 28 questions the 4 possible responses are 'Not at all' (1), 'A little' (2), 'Quite a bit' (3) and 'Very much' (4). For the remaining 2 questions the response is requested on a 7-point scale from 1 ('Very poor') to 7 ('Excellent'). The raw scale scores were linear transformed, producing scale scores that ranged from 0% to 100%. A high scale score represents a higher response level. Hence for the functional scales and the global health status a higher score indicates a better QoL, whilst for the symptom scale scores this is implied by a lower score.

    Time frame: Week 17 and Week 48

  25. Total Number of PRBC Units Transfused During the Open-Label Period

    Number of units of PRBC transfused to subjects in the open-label period are reported.

    Time frame: Week 17 to Week 48

07

Results

Posted Mar 25, 2022

Participant flow

This Phase 3, randomized, multicenter, open-label, active-comparator controlled study evaluated the efficacy and safety of pegcetacoplan (APL-2) in subjects with paroxysmal nocturnal hemoglobinuria who had received treatment with eculizumab (Soliris®) in the past.

Run-in Period (Day -28 to ≤Day 1)
Participant flow — Run-in Period (Day -28 to ≤Day 1)
MilestonePegcetacoplan to PegcetacoplanEculizumab to Pegcetacoplan
Started4139
Completed4139
Not completed00
RCP (Day 1 - Week 16)
Participant flow — RCP (Day 1 - Week 16)
MilestonePegcetacoplan to PegcetacoplanEculizumab to Pegcetacoplan
Started4139
Completed3839
Not completed30
Withdrew: Adverse event30
Open-label Period (Week 17 to Week 48)
Participant flow — Open-label Period (Week 17 to Week 48)
MilestonePegcetacoplan to PegcetacoplanEculizumab to Pegcetacoplan
Started3839
Completed3532
Not completed37
Withdrew: Adverse event37

Outcome measures

PrimaryLeast Squares (LS) Mean Change From Baseline to Week 16 in Hemoglobin (Hb) Level During the RCP

Baseline was the average of measurements recorded before taking the first dose of pegcetacoplan, which included local and central laboratory values during the screening period. Analysis excluded data before the RCP and was censored for transfusions.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · Grams per deciliter (g/dL)
Least Squares (LS) Mean Change From Baseline to Week 16 in Hemoglobin (Hb) Level During the RCP
Grams per deciliter (g/dL)Pegcetacoplan to PegcetacoplanEculizumab to Pegcetacoplan
Least Squares (LS) Mean Change From Baseline to Week 16 in Hemoglobin (Hb) Level During the RCP2.37 ± 0.363-1.47 ± 0.666
Statistical analysis
  • Pegcetacoplan to Pegcetacoplan vs Eculizumab to Pegcetacoplan · MMRM · p = <0.0001 (Superiority was tested at the 5% level. MMRM includes treatment + baseline value + analysis visit + strata + analysis visit × treatment, where strata is the combination of randomization stratification factors.) · Ls mean difference: 3.84 · 95% CI 2.33 to 5.34
SecondaryPercentage of Subjects Who Did Not Require a Transfusion (Transfusion Avoidance) During the RCP

Subjects who experienced more than 1 transfusion during the RCP are only counted once. Subjects who did not have a transfusion but withdrew before Week 16 were considered as having a transfusion in the analysis of transfusion avoidance.

Time frame:
Day 1 to Week 16
Reported as:
Number · Percentage of subjects
Percentage of Subjects Who Did Not Require a Transfusion (Transfusion Avoidance) During the RCP
Percentage of subjectsPegcetacoplan to PegcetacoplanEculizumab to Pegcetacoplan
Percentage of Subjects Who Did Not Require a Transfusion (Transfusion Avoidance) During the RCP85.415.4
Statistical analysis
  • Pegcetacoplan to Pegcetacoplan vs Eculizumab to Pegcetacoplan · Miettinen-Nurminen · p = <0.0001 (Non-inferiority was tested at the 2.5% level.) · Risk difference (rd): 0.6253 · 95% CI 0.4830 to 0.7677
SecondaryLS Mean Change From Baseline to Week 16 in Absolute Reticulocyte Count (ARC) During the RCP

Baseline was the average of available measurements recorded from central laboratory before taking the first dose of pegcetacoplan. Analysis excluded data before the RCP and was censored for transfusions.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · 10^9 cells/ liter (L)
LS Mean Change From Baseline to Week 16 in Absolute Reticulocyte Count (ARC) During the RCP
10^9 cells/ liter (L)Pegcetacoplan to PegcetacoplanEculizumab to Pegcetacoplan
LS Mean Change From Baseline to Week 16 in Absolute Reticulocyte Count (ARC) During the RCP-135.82 ± 6.54327.79 ± 11.859
Statistical analysis
  • Pegcetacoplan to Pegcetacoplan vs Eculizumab to Pegcetacoplan · MMRM · p = <0.0001 (Non-inferiority was tested at the 2.5% level. MMRM includes treatment + baseline value + analysis visit + strata + analysis visit × treatment, where strata is the combination of randomization stratification factors.) · Ls mean difference: -163.61 · 95% CI -189.91 to -137.30
SecondaryLS Mean Change From Baseline to Week 16 in Lactate Dehydrogenase (LDH) Level During the RCP

Baseline was the average of available measurements recorded from central laboratory before taking the first dose of pegcetacoplan. Analysis excluded data before the RCP and was censored for transfusions.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · Units (U)/L
LS Mean Change From Baseline to Week 16 in Lactate Dehydrogenase (LDH) Level During the RCP
Units (U)/LPegcetacoplan to PegcetacoplanEculizumab to Pegcetacoplan
LS Mean Change From Baseline to Week 16 in Lactate Dehydrogenase (LDH) Level During the RCP-14.76 ± 42.708-10.12 ± 71.025
Statistical analysis
  • Pegcetacoplan to Pegcetacoplan vs Eculizumab to Pegcetacoplan · MMRM · p = 0.9557 (Non-inferiority was tested at the 2.5% level. MMRM includes treatment + baseline value + analysis visit + strata + analysis visit × treatment, where strata is the combination of randomization stratification factors.) · Ls mean difference: -4.63 · 95% CI -181.30 to 172.04
SecondaryLS Mean Change From Baseline to Week 16 in Functional Assessment of Chronic Illness Therapy (FACIT) - Fatigue Scale Score During the RCP

The FACIT-fatigue scale version 4 is a 13-item Likert scaled instrument where the subject was presented with 13 statements and asked to indicate their response as it applied to the past 7 days. The 5 possible responses were 'Not at all' (0), 'A little bit (1), 'Somewhat' (2), 'Quite a bit' (3) and 'Very much' (4). With 13 statements the total score had a range of 0 to 52. A higher score corresponds to a higher quality of life (QoL). Baseline was the last available, nonmissing observation before taking the first dose of pegcetacoplan. Data collected after transfusion is excluded from analysis.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · Score on a scale
LS Mean Change From Baseline to Week 16 in Functional Assessment of Chronic Illness Therapy (FACIT) - Fatigue Scale Score During the RCP
Score on a scalePegcetacoplan to PegcetacoplanEculizumab to Pegcetacoplan
LS Mean Change From Baseline to Week 16 in Functional Assessment of Chronic Illness Therapy (FACIT) - Fatigue Scale Score During the RCP9.22 ± 1.607-2.65 ± 2.821
Statistical analysis
  • Pegcetacoplan to Pegcetacoplan vs Eculizumab to Pegcetacoplan · MMRM · p = 0.0005 (MRMM includes treatment + baseline value + analysis visit + strata + analysis visit × treatment, where strata is the combination of randomization stratification factors.) · Ls mean difference: 11.87 · 95% CI 5.49 to 18.25
SecondaryPercentage of Subjects Who Achieved a Hb Response in the Absence of Transfusions at Week 16

Hb response was defined as an increase of at least 1 g/dL in Hb from Baseline at Week 16. Baseline was the average of measurements recorded before taking the first dose of pegcetacoplan, which included local and central laboratory values during the screening period. Analysis excluded data before the RCP and was censored for transfusions.

Time frame:
Baseline and Week 16
Reported as:
Number · Percentage of subjects
Percentage of Subjects Who Achieved a Hb Response in the Absence of Transfusions at Week 16
Percentage of subjectsPegcetacoplan to PegcetacoplanEculizumab to Pegcetacoplan
Percentage of Subjects Who Achieved a Hb Response in the Absence of Transfusions at Week 1675.60.0
Statistical analysis
  • Pegcetacoplan to Pegcetacoplan vs Eculizumab to Pegcetacoplan · Difference in percentage: 0.6745 · 95% CI 0.5452 to 0.8039The difference in percentage and 95% CI is calculated based on stratified Miettinen-Nurminen method stratified by randomization factor so it it is not a direct difference of two reporting groups.
SecondaryPercentage of Subjects Who Achieved Reticulocyte Normalization in the Absence of Transfusions at Week 16

Reticulocyte normalization was defined as the ARC being below the upper limit of the gender-specific normal range at Week 16, censored for transfusions. Subjects who received a transfusion between Day 1 and Week 16 or withdrew without providing efficacy data at Week 16 were classified as nonresponders.

Time frame:
Week 16
Reported as:
Number · Percentage of subjects
Percentage of Subjects Who Achieved Reticulocyte Normalization in the Absence of Transfusions at Week 16
Percentage of subjectsPegcetacoplan to PegcetacoplanEculizumab to Pegcetacoplan
Percentage of Subjects Who Achieved Reticulocyte Normalization in the Absence of Transfusions at Week 1678.02.6
Statistical analysis
  • Pegcetacoplan to Pegcetacoplan vs Eculizumab to Pegcetacoplan · Difference in percentage: 0.6639 · 95% CI 0.5309 to 0.7968The difference in percentage and 95% CI is calculated based on stratified Miettinen-Nurminen method stratified by randomization factor so it it is not a direct difference of two reporting groups.
SecondaryPercentage of Subjects Who Achieved Hb Normalization in the Absence of Transfusions at Week 16

Hb normalization was defined as the Hb level being above the lower limit of the normal range at Week 16, censored for transfusions. Subjects who received a transfusion between Day 1 and Week 16 or withdrew without providing efficacy data at Week 16 are classified as nonnormalization.

Time frame:
Week 16
Reported as:
Number · Percentage of subjects
Percentage of Subjects Who Achieved Hb Normalization in the Absence of Transfusions at Week 16
Percentage of subjectsPegcetacoplan to PegcetacoplanEculizumab to Pegcetacoplan
Percentage of Subjects Who Achieved Hb Normalization in the Absence of Transfusions at Week 1634.10.0
Statistical analysis
  • Pegcetacoplan to Pegcetacoplan vs Eculizumab to Pegcetacoplan · Difference in percentage: 0.3043 · 95% CI 0.1493 to 0.4593The difference in percentage and 95% CI is calculated based on stratified Miettinen-Nurminen method stratified by randomization factor so it it is not a direct difference of two reporting groups.
SecondaryLS Mean Change From Baseline to Week 16 in Indirect Bilirubin Level During the RCP

Baseline was the average of available measurements recorded from central laboratory before taking the first dose of pegcetacoplan. Analysis excluded data before the RCP and was censored for transfusions.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · Micromole (μmol)/L
LS Mean Change From Baseline to Week 16 in Indirect Bilirubin Level During the RCP
Micromole (μmol)/LPegcetacoplan to PegcetacoplanEculizumab to Pegcetacoplan
LS Mean Change From Baseline to Week 16 in Indirect Bilirubin Level During the RCP-17.78 ± 2.7274.15 ± 4.477
Statistical analysis
  • Pegcetacoplan to Pegcetacoplan vs Eculizumab to Pegcetacoplan · MMRM · p = 0.0002 (MMRM includes treatment + baseline value + analysis visit + strata + analysis visit × treatment, where strata is the combination of randomization stratification factors.) · Ls mean difference: -21.93 · 95% CI -32.49 to -11.36
SecondaryLS Mean Change From Baseline to Week 16 in Haptoglobin Level During the RCP

Baseline was the average of available measurements recorded from central laboratory before taking the first dose of pegcetacoplan. Analysis excluded data before the RCP and was censored for transfusions.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · g/L
LS Mean Change From Baseline to Week 16 in Haptoglobin Level During the RCP
g/LPegcetacoplan to PegcetacoplanEculizumab to Pegcetacoplan
LS Mean Change From Baseline to Week 16 in Haptoglobin Level During the RCP-0.02 ± 0.0330.12 ± 0.063
Statistical analysis
  • Pegcetacoplan to Pegcetacoplan vs Eculizumab to Pegcetacoplan · MMRM · p = 0.0369 (MMRM includes treatment + baseline value + analysis visit + strata + analysis visit × treatment, where strata is the combination of randomization stratification factors.) · Ls mean difference: -0.14 · 95% CI -0.28 to -0.01
SecondaryLS Mean Change From Baseline to Week 16 in Linear Analog Scale Assessment (LASA) Scores During the RCP

The LASA consists of 3 items, where the respondents were asked to rate their perceived level of functioning. Specific domains included activity level, ability to carry out daily activities, and an item for overall QoL. Their level of functioning was reported on a 0 to 100 scale with 0 indicates "As low as could be" and 100 indicates "As high as could be". The combined score ranged from 0 to 300, with higher scores corresponding to a higher QoL.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · Score on a scale
LS Mean Change From Baseline to Week 16 in Linear Analog Scale Assessment (LASA) Scores During the RCP
Score on a scalePegcetacoplan to PegcetacoplanEculizumab to Pegcetacoplan
LS Mean Change From Baseline to Week 16 in Linear Analog Scale Assessment (LASA) Scores During the RCP49.38 ± 10.189-9.72 ± 18.988
Statistical analysis
  • Pegcetacoplan to Pegcetacoplan vs Eculizumab to Pegcetacoplan · MMRM · p = 0.0069 (MMRM includes treatment + baseline value + analysis visit + strata + analysis visit × treatment, where strata is the combination of randomization stratification factors.) · Ls mean difference: 59.10 · 95% CI 16.88 to 101.32
SecondaryLS Mean Change From Baseline to Week 16 in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Core 30 Scale (QLQ-C30) Scores During the RCP

The EORTC QLQ-C30 questionnaire (version 3.0) consists of 30 questions comprised of both multi-item scales and single-item measures to assess overall QoL in subjects. Questions are designated by functional scales, symptom scales, and global subject QoL/overall perceived health status. For the first 28 questions the 4 possible responses are "Not at all' (1), 'A little' (2), 'Quite a bit' (3) and 'Very much' (4). For the remaining 2 questions the response is requested on a 7-point scale from 1 ('Very poor') to 7 ('Excellent'). The raw scale scores were linear transformed, producing scale scores that ranged from 0% to 100%. A high scale score represents a higher response level. Hence for the functional scales and the global health status a higher score indicates a better QoL, whilst for the symptom scale scores this is implied by a lower score.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · Score on a scale
LS Mean Change From Baseline to Week 16 in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Core 30 Scale (QLQ-C30) Scores During the RCP
Score on a scalePegcetacoplan to PegcetacoplanEculizumab to Pegcetacoplan
Global Health Status/QoL15.91 ± 3.635-2.71 ± 8.515
Functional Scales - Physical functioning16.92 ± 2.0814.06 ± 3.605
Functional Scales - Role functioning15.39 ± 3.930-9.04 ± 6.954
Functional Scales - Emotional functioning7.98 ± 3.3663.86 ± 7.237
Functional Scales - Cognitive functioning5.76 ± 3.258-3.80 ± 6.420
Functional Scales - Social functioning15.08 ± 2.9463.82 ± 6.349
Symptom Scales - Fatigue-22.93 ± 3.321-2.18 ± 6.644
Symptom Scales - Nausea and vomiting-0.34 ± 1.632-0.33 ± 3.876
Symptom Scales - Pain-0.74 ± 4.3232.01 ± 7.841
Symptom Scales - Dyspnoea-20.12 ± 3.488-5.55 ± 7.019
Symptom Scales - Insomnia-9.18 ± 3.955-9.50 ± 7.090
Symptom Scales - Appetite loss-3.76 ± 3.3574.19 ± 7.009
Symptom Scales - Constipation2.98 ± 3.2481.19 ± 8.129
Symptom Scales - Diarrhoea0.31 ± 3.7111.68 ± 8.204
Symptom Scales - Financial difficulties-6.82 ± 3.8530.58 ± 6.297
Statistical analysis
  • Pegcetacoplan to Pegcetacoplan vs Eculizumab to Pegcetacoplan · MMRM · p = 0.0486 (MMRM includes treatment + baseline value + analysis visit + strata + analysis visit × treatment, where strata is the combination of randomization stratification factors.) · Ls mean difference: 18.62 · 95% CI 0.12 to 37.13
  • Pegcetacoplan to Pegcetacoplan vs Eculizumab to Pegcetacoplan · MMRM · p = 0.0023 (MMRM includes treatment + baseline value + analysis visit + strata + analysis visit × treatment, where strata is the combination of randomization stratification factors.) · Ls mean difference: 12.86 · 95% CI 4.86 to 20.86
  • Pegcetacoplan to Pegcetacoplan vs Eculizumab to Pegcetacoplan · MMRM · p = 0.0027 (MMRM includes treatment + baseline value + analysis visit + strata + analysis visit × treatment, where strata is the combination of randomization stratification factors.) · Ls mean difference: 24.43 · 95% CI 8.84 to 40.01
  • Pegcetacoplan to Pegcetacoplan vs Eculizumab to Pegcetacoplan · MMRM · p = 0.6013 (MMRM includes treatment + baseline value + analysis visit + strata + analysis visit × treatment, where strata is the combination of randomization stratification factors.) · Ls mean difference: 4.11 · 95% CI -11.58 to 19.80
  • Pegcetacoplan to Pegcetacoplan vs Eculizumab to Pegcetacoplan · MMRM · p = 0.1792 (MMRM includes treatment + baseline value + analysis visit + strata + analysis visit × treatment, where strata is the combination of randomization stratification factors.) · Ls mean difference: 9.56 · 95% CI -4.52 to 23.64
  • Pegcetacoplan to Pegcetacoplan vs Eculizumab to Pegcetacoplan · MMRM · p = 0.1039 (MMRM includes treatment + baseline value + analysis visit + strata + analysis visit × treatment, where strata is the combination of randomization stratification factors.) · Ls mean difference: 11.27 · 95% CI -2.38 to 24.92
  • Pegcetacoplan to Pegcetacoplan vs Eculizumab to Pegcetacoplan · MMRM · p = 0.0062 (MMRM includes treatment + baseline value + analysis visit + strata + analysis visit × treatment, where strata is the combination of randomization stratification factors.) · Ls mean difference: -20.74 · 95% CI -35.29 to -6.19
  • Pegcetacoplan to Pegcetacoplan vs Eculizumab to Pegcetacoplan · MMRM · p = 0.9975 (MMRM includes treatment + baseline value + analysis visit + strata + analysis visit × treatment, where strata is the combination of randomization stratification factors.) · Ls mean difference: -0.01 · 95% CI -8.38 to 8.35
  • Pegcetacoplan to Pegcetacoplan vs Eculizumab to Pegcetacoplan · MMRM · p = 0.7554 (MMRM includes treatment + baseline value + analysis visit + strata + analysis visit × treatment, where strata is the combination of randomization stratification factors.) · Ls mean difference: -2.76 · 95% CI -20.36 to 14.85
  • Pegcetacoplan to Pegcetacoplan vs Eculizumab to Pegcetacoplan · MMRM · p = 0.0620 (MMRM includes treatment + baseline value + analysis visit + strata + analysis visit × treatment, where strata is the combination of randomization stratification factors.) · Ls mean difference: -14.57 · 95% CI -29.90 to 0.76
  • Pegcetacoplan to Pegcetacoplan vs Eculizumab to Pegcetacoplan · MMRM · p = 0.9686 (MMRM includes treatment + baseline value + analysis visit + strata + analysis visit × treatment, where strata is the combination of randomization stratification factors.) · Ls mean difference: 0.32 · 95% CI -15.67 to 16.30
  • Pegcetacoplan to Pegcetacoplan vs Eculizumab to Pegcetacoplan · MMRM · p = 0.3002 (MMRM includes treatment + baseline value + analysis visit + strata + analysis visit × treatment, where strata is the combination of randomization stratification factors.) · Ls mean difference: -7.95 · 95% CI -23.23 to 7.33
  • Pegcetacoplan to Pegcetacoplan vs Eculizumab to Pegcetacoplan · MMRM · p = 0.8374 (MMRM includes treatment + baseline value + analysis visit + strata + analysis visit × treatment, where strata is the combination of randomization stratification factors.) · Ls mean difference: 1.79 · 95% CI -15.70 to 19.29
  • Pegcetacoplan to Pegcetacoplan vs Eculizumab to Pegcetacoplan · MMRM · p = 0.8775 (MMRM includes treatment + baseline value + analysis visit + strata + analysis visit × treatment, where strata is the combination of randomization stratification factors.) · Ls mean difference: -1.38 · 95% CI -19.28 to 16.52
  • Pegcetacoplan to Pegcetacoplan vs Eculizumab to Pegcetacoplan · MMRM · p = 0.3066 (MMRM includes treatment + baseline value + analysis visit + strata + analysis visit × treatment, where strata is the combination of randomization stratification factors.) · Ls mean difference: -7.40 · 95% CI -21.76 to 6.95
SecondaryTotal Number of PRBC Units Transfused During the RCP

Subjects who withdrew during the RCP before Week 16 will have their number of units of PRBC estimated from the duration they were in the study.

Time frame:
Day 1 to Week 16
Reported as:
Number · PRBC units
Total Number of PRBC Units Transfused During the RCP
PRBC unitsPegcetacoplan to PegcetacoplanEculizumab to Pegcetacoplan
Total Number of PRBC Units Transfused During the RCP26198
Statistical analysis
  • Pegcetacoplan to Pegcetacoplan vs Eculizumab to Pegcetacoplan · Wilcoxon rank-sum test · p = <0.0001 · Median difference (final values): 3.0 · 95% CI 2.0 to 4.0
SecondaryMean Change From Baseline to Week 48 in Hb Level During the Treatment Period

Baseline was the average of measurements recorded before taking the first dose of pegcetacoplan, which included local and central laboratory values during the screening period. Analysis excluded data before the RCP and was censored for transfusions.

Time frame:
Baseline and Week 48
Reported as:
Mean · g/dL
Mean Change From Baseline to Week 48 in Hb Level During the Treatment Period
g/dLPegcetacoplan to PegcetacoplanEculizumab to Pegcetacoplan
Mean Change From Baseline to Week 48 in Hb Level During the Treatment Period2.47 ± 1.722.93 ± 2.09
SecondaryMean Change From Week 17 to Week 48 in Hb Level During the Open-label Period

Baseline was the average of measurements recorded before taking the first dose of pegcetacoplan, which included local and central laboratory values during the screening period. Analysis excluded data before the RCP and was censored for transfusions.

Time frame:
Week 17 and Week 48
Reported as:
Mean · g/dL
Mean Change From Week 17 to Week 48 in Hb Level During the Open-label Period
g/dLOpen-label Period: Continue PegcetacoplanOpen-label Period: Crossover to Pegcetacoplan
Mean Change From Week 17 to Week 48 in Hb Level During the Open-label Period-0.16 ± 1.1542.89 ± 2.078
SecondaryMean Change From Baseline to Week 48 in ARC During the Treatment Period

Baseline was the average of available measurements recorded from central laboratory before taking the first dose of pegcetacoplan. Analysis excluded data before the RCP and was censored for transfusions.

Time frame:
Baseline and Week 48
Reported as:
Mean · 10^9 cells/L
Mean Change From Baseline to Week 48 in ARC During the Treatment Period
10^9 cells/LPegcetacoplan to PegcetacoplanEculizumab to Pegcetacoplan
Mean Change From Baseline to Week 48 in ARC During the Treatment Period-135.64 ± 67.90-128.22 ± 59.60
SecondaryMean Change From Week 17 to Week 48 in ARC During the Open-label Period

Baseline was the average of available measurements recorded from central laboratory before taking the first dose of pegcetacoplan. Analysis excluded data before the RCP and was censored for transfusions.

Time frame:
Week 17 and Week 48
Reported as:
Mean · 10^9 cells/L
Mean Change From Week 17 to Week 48 in ARC During the Open-label Period
10^9 cells/LOpen-label Period: Continue PegcetacoplanOpen-label Period: Crossover to Pegcetacoplan
Mean Change From Week 17 to Week 48 in ARC During the Open-label Period-6.50 ± 26.471-121.15 ± 70.969
SecondaryMean Change From Baseline to Week 48 in LDH Level During the Treatment Period

Baseline was the average of available measurements recorded from central laboratory before taking the first dose of pegcetacoplan. Analysis excluded data before the RCP and was censored for transfusions.

Time frame:
Baseline and Week 48
Reported as:
Mean · U/L
Mean Change From Baseline to Week 48 in LDH Level During the Treatment Period
U/LPegcetacoplan to PegcetacoplanEculizumab to Pegcetacoplan
Mean Change From Baseline to Week 48 in LDH Level During the Treatment Period-41.53 ± 153.68-105.27 ± 315.59
SecondaryMean Change From Week 17 to Week 48 in LDH Level During the Open-label Period

Baseline was the average of available measurements recorded from central laboratory before taking the first dose of pegcetacoplan. Analysis excluded data before the RCP and was censored for transfusions.

Time frame:
Week 17 and Week 48
Reported as:
Mean · U/L
Mean Change From Week 17 to Week 48 in LDH Level During the Open-label Period
U/LOpen-label Period: Continue PegcetacoplanOpen-label Period: Crossover to Pegcetacoplan
Mean Change From Week 17 to Week 48 in LDH Level During the Open-label Period8.03 ± 129.285-46.84 ± 292.607
SecondaryMean Change From Baseline to Week 48 in FACIT-Fatigue Scale Score During the Treatment Period

The FACIT-fatigue scale version 4 is a 13-item Likert scaled instrument where the subject was presented with 13 statements and asked to indicate their response as it applied to the past 7 days. The 5 possible responses were 'Not at all' (0), 'A little bit (1), 'Somewhat' (2), 'Quite a bit' (3) and 'Very much' (4). With 13 statements the total score had a range of 0 to 52. A higher score corresponds to a higher QoL. Baseline was the last available, nonmissing observation before taking the first dose of pegcetacoplan. Data collected after transfusion is excluded from analysis.

Time frame:
Baseline and Week 48
Reported as:
Mean · Score on a scale
Mean Change From Baseline to Week 48 in FACIT-Fatigue Scale Score During the Treatment Period
Score on a scalePegcetacoplan to PegcetacoplanEculizumab to Pegcetacoplan
Mean Change From Baseline to Week 48 in FACIT-Fatigue Scale Score During the Treatment Period10.14 ± 9.069.62 ± 10.34
SecondaryMean Change From Week 17 to Week 48 in FACIT-Fatigue Scale Score During the Open-label Period

The FACIT-fatigue scale is a 13 item Likert scaled instrument where the subject was presented with 13 statements and asked to indicate their response as it applied to the past 7 days. The 5 possible responses were 'Not at all' (0), 'A little bit (1), 'Somewhat' (2), 'Quite a bit' (3) and 'Very much' (4). With 13 statements the total score had a range of 0 to 52. Higher score corresponds to a higher QoL.

Time frame:
Week 17 and Week 48
Reported as:
Mean · Score on a scale
Mean Change From Week 17 to Week 48 in FACIT-Fatigue Scale Score During the Open-label Period
Score on a scaleOpen-label Period: Continue PegcetacoplanOpen-label Period: Crossover to Pegcetacoplan
Mean Change From Week 17 to Week 48 in FACIT-Fatigue Scale Score During the Open-label Period1.28 ± 7.80510.19 ± 10.973
SecondaryMean Change From Baseline to Week 48 in LASA Scores During the Treatment Period

The LASA consists of 3 items, where the respondents were asked to rate their perceived level of functioning. Specific domains included activity level, ability to carry out daily activities, and an item for overall QoL. Their level of functioning was reported on a 0 to 100 scale with 0 indicates "As low as could be" and 100 indicates "As high as could be". The combined score ranged from 0 to 300, with higher scores corresponding to a higher QoL.

Time frame:
Baseline and Week 48
Reported as:
Mean · Score on a scale
Mean Change From Baseline to Week 48 in LASA Scores During the Treatment Period
Score on a scalePegcetacoplan to PegcetacoplanEculizumab to Pegcetacoplan
Mean Change From Baseline to Week 48 in LASA Scores During the Treatment Period58.66 ± 51.1656.52 ± 65.55
SecondaryMean Change From Week 17 to Week 48 in LASA Scores During the Open-label Period

The FACIT-fatigue scale is a 13 item Likert scaled instrument where the subject was presented with 13 statements and asked to indicate their response as it applied to the past 7 days. The 5 possible responses were 'Not at all' (0), 'A little bit (1), 'Somewhat' (2), 'Quite a bit' (3) and 'Very much' (4). With 13 statements the total score had a range of 0 to 52. Higher score corresponds to a higher QoL.

Time frame:
Week 17 and Week 48
Reported as:
Mean · Score on a scale
Mean Change From Week 17 to Week 48 in LASA Scores During the Open-label Period
Score on a scaleOpen-label Period: Continue PegcetacoplanOpen-label Period: Crossover to Pegcetacoplan
Mean Change From Week 17 to Week 48 in LASA Scores During the Open-label Period13.13 ± 46.29662.92 ± 60.053
SecondaryMean Change From Baseline to Week 48 in QLQ-C30 Scores During the Treatment Period

The EORTC QLQ-C30 questionnaire (version 3.0) consists of 30 questions comprised of both multi-item scales and single-item measures to assess overall QoL in subjects. Questions are designated by functional scales, symptom scales, and global subject QoL/overall perceived health status. For the first 28 questions the 4 possible responses are 'Not at all' (1), 'A little' (2), 'Quite a bit' (3) and 'Very much' (4). For the remaining 2 questions the response is requested on a 7-point scale from 1 ('Very poor') to 7 ('Excellent'). The raw scale scores were linear transformed, producing scale scores that ranged from 0% to 100%. A high scale score represents a higher response level. Hence for the functional scales and the global health status a higher score indicates a better QoL, whilst for the symptom scale scores this is implied by a lower score.

Time frame:
Baseline and Week 48
Reported as:
Mean · Score on a scale
Mean Change From Baseline to Week 48 in QLQ-C30 Scores During the Treatment Period
Score on a scalePegcetacoplan to PegcetacoplanEculizumab to Pegcetacoplan
Global Health Status/QoL18.89 ± 17.63513.99 ± 22.912
Functional Scales - Physical functioning15.33 ± 15.27810.80 ± 17.765
Functional Scales - Role functioning16.67 ± 27.33420.11 ± 27.595
Functional Scales - Emotional functioning10.28 ± 18.6575.36 ± 17.005
Functional Scales - Cognitive functioning7.78 ± 23.4620.00 ± 18.703
Functional Scales - Social functioning16.11 ± 24.16614.88 ± 22.379
Symptom Scales - Fatigue-21.48 ± 26.733-23.75 ± 29.506
Symptom Scales - Nausea and vomiting-2.22 ± 11.3570.00 ± 4.454
Symptom Scales - Pain0.56 ± 27.8493.45 ± 20.596
Symptom Scales - Dyspnoea-17.78 ± 29.985-27.59 ± 33.415
Symptom Scales - Insomnia-6.67 ± 25.3710.00 ± 28.172
Symptom Scales - Appetite loss-7.78 ± 14.339-3.45 ± 22.440
Symptom Scales - Constipation-1.11 ± 22.289-2.38 ± 8.742
Symptom Scales - Diarrhoea1.11 ± 29.6645.95 ± 15.853
Symptom Scales - Financial difficulties-15.56 ± 24.343-8.33 ± 19.510
SecondaryMean Change From Week 17 to Week 48 in QLQ-C30 Scores During the Open-label Period

The EORTC QLQ-C30 questionnaire (version 3.0) consists of 30 questions comprised of both multi-item scales and single-item measures to assess overall QoL in subjects. Questions are designated by functional scales, symptom scales, and global subject QoL/overall perceived health status. For the first 28 questions the 4 possible responses are 'Not at all' (1), 'A little' (2), 'Quite a bit' (3) and 'Very much' (4). For the remaining 2 questions the response is requested on a 7-point scale from 1 ('Very poor') to 7 ('Excellent'). The raw scale scores were linear transformed, producing scale scores that ranged from 0% to 100%. A high scale score represents a higher response level. Hence for the functional scales and the global health status a higher score indicates a better QoL, whilst for the symptom scale scores this is implied by a lower score.

Time frame:
Week 17 and Week 48
Reported as:
Mean · Score on a scale
Mean Change From Week 17 to Week 48 in QLQ-C30 Scores During the Open-label Period
Score on a scaleOpen-label Period: Continue PegcetacoplanOpen-label Period: Crossover to Pegcetacoplan
Global Health Status/QoL7.22 ± 19.66423.08 ± 22.149
Functional Scales - Physical functioning0.89 ± 10.16811.03 ± 17.173
Functional Scales - Role functioning5.00 ± 20.59919.87 ± 22.617
Functional Scales - Emotional functioning-2.22 ± 27.3281.92 ± 13.806
Functional Scales - Cognitive functioning-2.78 ± 16.9992.56 ± 24.355
Functional Scales - Social functioning3.89 ± 18.91912.18 ± 23.361
Symptom Scales - Fatigue-2.96 ± 20.824-23.08 ± 28.790
Symptom Scales - Nausea and vomiting-2.22 ± 5.762-4.49 ± 12.072
Symptom Scales - Pain-2.78 ± 23.195-5.77 ± 21.051
Symptom Scales - Dyspnoea3.33 ± 25.295-19.23 ± 28.555
Symptom Scales - Insomnia8.89 ± 23.050-5.13 ± 27.797
Symptom Scales - Appetite loss-8.89 ± 26.164-5.13 ± 22.494
Symptom Scales - Constipation-1.11 ± 20.498-1.28 ± 11.473
Symptom Scales - Diarrhoea-4.44 ± 28.6793.85 ± 27.206
Symptom Scales - Financial difficulties-2.22 ± 12.172-2.56 ± 16.119
SecondaryTotal Number of PRBC Units Transfused During the Open-Label Period

Number of units of PRBC transfused to subjects in the open-label period are reported.

Time frame:
Week 17 to Week 48
Reported as:
Number · PRBC Units
Total Number of PRBC Units Transfused During the Open-Label Period
PRBC UnitsOpen-label Period: Continue PegcetacoplanOpen-label Period: Crossover to PegcetacoplanOpen-label Run-in Period: Crossover to Pegcetacoplan
Total Number of PRBC Units Transfused During the Open-Label Period6811014

Adverse events

Collected over Day -28 to Week 54, a maximum of approximately 58 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Run-in Period: Pegcetacoplan + Eculizumab0/80 (0%)4/80 (5%)71/80 (88.8%)
Open-label Period: Pegcetacoplan1/77 (1.3%)18/77 (23.4%)71/77 (92.2%)
RCP: Eculizumab0/39 (0%)5/39 (12.8%)36/39 (92.3%)
RCP: Pegcetacoplan0/41 (0%)7/41 (17.1%)36/41 (87.8%)
Most frequent serious events
Showing 10 of 36
Most frequent serious events
EventRun-in Period: Pegcetacoplan + EculizumabOpen-label Period: PegcetacoplanRCP: EculizumabRCP: Pegcetacoplan
HaemolysisBlood and lymphatic system disorders1/805/771/392/41
AnaemiaBlood and lymphatic system disorders0/800/772/390/41
GastroenteritisInfections and infestations0/802/770/391/41
HyperthermiaGeneral disorders0/800/771/390/41
Haemolytic anaemiaBlood and lymphatic system disorders0/801/771/390/41
Abdominal painGastrointestinal disorders0/801/771/390/41
Hepatocellular injuryHepatobiliary disorders0/800/771/390/41
HyperbilirubinaemiaHepatobiliary disorders0/800/771/390/41
JaundiceHepatobiliary disorders0/800/771/390/41
SepsisInfections and infestations2/801/770/390/41
Most frequent other events
Showing 10 of 48
Most frequent other events
EventRun-in Period: Pegcetacoplan + EculizumabOpen-label Period: PegcetacoplanRCP: EculizumabRCP: Pegcetacoplan
Injection site erythemaGeneral disorders33/809/770/397/41
HaemolysisBlood and lymphatic system disorders1/8013/779/394/41
HeadacheNervous system disorders10/808/779/392/41
DiarrhoeaGastrointestinal disorders10/8011/772/399/41
NasopharyngitisInfections and infestations4/8012/772/393/41
FatigueGeneral disorders5/808/776/392/41
Injection site pruritusGeneral disorders12/805/770/391/41
AstheniaGeneral disorders1/804/775/393/41
AnaemiaBlood and lymphatic system disorders1/802/775/390/41
DizzinessNervous system disorders3/803/775/391/41

Baseline characteristics

The intent-to-treat (ITT) set included all randomized subjects.

Age, Categorical
Age, Categorical(Participants)Pegcetacoplan to PegcetacoplanEculizumab to PegcetacoplanTotal
<=18 years000
Between 18 and 65 years313263
>=65 years10717
Sex: Female, Male
Sex: Female, Male(Participants)Pegcetacoplan to PegcetacoplanEculizumab to PegcetacoplanTotal
Female272249
Male141731
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Pegcetacoplan to PegcetacoplanEculizumab to PegcetacoplanTotal
Hispanic or Latino213
Not Hispanic or Latino293261
Unknown or Not Reported10616
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Pegcetacoplan to PegcetacoplanEculizumab to PegcetacoplanTotal
Asian5712
Black or African American202
White242549
Other011
Not Reported10616
Number of transfusions in the last 12 months prior to Day -28
Number of transfusions in the last 12 months prior to Day -28(Participants)Pegcetacoplan to PegcetacoplanEculizumab to PegcetacoplanTotal
< 4201636
≥ 4212344
Platelet count at screening
Platelet count at screening(Participants)Pegcetacoplan to PegcetacoplanEculizumab to PegcetacoplanTotal
<100,000 (count/mm^3)12921
≥100,000 (count/mm^3)293059
08

Study locations

53 sites
  • University of Southern California
    Los Angeles, California 90033, United States
  • Sarcoma Oncology Research Center
    Santa Monica, California 90403, United States
  • Denver Health
    Denver, Colorado 80204, United States
  • Georgetown University Hospital
    Washington, District of Columbia 20057, United States
  • Cancer Specialists of North Florida
    Jacksonville, Florida 32256, United States
  • Lakes Research
    Miami Lakes, Florida 33014, United States
  • Mid Florida Hematology and Oncology
    Orange City, Florida 32763, United States
  • Winship Cancer Institute of Emory University
    Atlanta, Georgia 30322, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • Investigative Clinical Research of Indiana
    Indianapolis, Indiana 46260, United States
  • Cancer & Hematology Centers of Western Michigan
    Grand Rapids, Michigan 49503, United States
  • New York Cancer & Blood Specialists
    Bronx, New York 10469, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
  • New York Cancer & Blood Specialists
    East Setauket, New York 11733, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Good Samaritan Hospital
    Corvallis, Oregon 97330, United States
  • University of Tennessee Medical Center
    Knoxville, Tennessee 37920, United States
  • Baptist Cancer Center
    Memphis, Tennessee 38120, United States
  • HOPE Cancer Center of East Texas
    Tyler, Texas 75701, United States
  • Royal Melbourne Hospital
    Melbourne, Victoria 3000, Australia
  • Cliniques Universitaires Saint-Luc
    Woluwe-Saint-Lambert, Vlaams-Brabant 1200, Belgium
  • AZ Delta Campus Wilgenstraat
    Roeselare, West-Vlaanderen 8800, Belgium
  • University of Alberta
    Edmonton, Alberta T6G 2G3, Canada
  • Toronto General Hospital
    Toronto, Ontario M9A1G2, Canada
  • Centre Hospitalier Annecy Genevois
    Annecy, 74374, France
  • Centre Hospitalier William Morey
    Chalon-sur-Saône, 71100, France
  • Centre Hospitalier Universitaire de Lille
    Lille, 59037, France
  • Institut Paoli-Calmettes Marseille
    Marseille, 13009, France
  • Hôpital Saint-Louis
    Paris, 75010, France
  • Centre Hospitalier Lyon Sud
    Pierre-Bénite, 69495, France
  • Centre Hospitalier de Saint-Quentin
    Saint-Quentin, 02321, France
  • Institut Universitaire du Cancer Toulouse - Oncopole
    Toulouse, 31059, France
  • Universitätsklinikum Ulm
    Ulm, Baden-Württemberg 89081, Germany
  • Uniklinik RWTH Aachen
    Aachen, North Rhine-Westphalia 52074, Germany
  • Universitätsklinikum Essen
    Essen, North Rhine-Westphalia 45147, Germany
  • Universitätsklinikum Hamburg Eppendorf
    Hamburg, 20246, Germany
  • Japanese Red Cross Nagoya Daiichi Hospital
    Nagoya, Aichi 453-8511, Japan
  • Japanese Red Cross Nagoya Daini Hospital
    Showa-ku, Aichi 453-8650, Japan
  • University of Tsukuba Hospital
    Tsukuba, Ibaraki 305-8576, Japan
  • Shinshu University Hospital
    Matsumoto, Nagano 390-8621, Japan
  • Okayama University Hospital
    Okayama-shi, Okayama 700-8558, Japan
  • Juntendo University Hospital
    Bunkyo-ku, Tokyo 113-8421, Japan
  • NTT Medical Center Tokyo
    Shinagawa-ku, Tokyo 141-8625, Japan
  • Kinan Hospital
    Tanabe, Wakayama 646-8588, Japan
  • Soonchunhyang University Bucheon Hospital
    Bucheon, 14584, Korea, Republic of
  • Chungnam National University Hospital
    Daejeon, 35015, Korea, Republic of
  • Samsung Medical Center
    Seoul, 06351, Korea, Republic of
  • Pavlov First Saint Petersburg State Medical University of Russian Ministry of Health
    Saint Petersburg, 197022, Russian Federation
  • Pavlov First Saint Petersburg State Medical University
    Saint Petersburg, 197022, Russian Federation
  • Institution of Health Care of Tyumen Region
    Tyumen, 625023, Russian Federation
  • Hospital Universitario de Gran Canaria Dr. Negrín
    Las Palmas De Gran Canaria, 35010, Spain
  • Hospital Universitario Politécnico La Fe
    Valencia, 46026, Spain
  • St. James' Institute of Oncology, Leeds Teaching Hospitals
    Leeds, LS9 7TF, United Kingdom
09

References and documents

Publications

  • de Latour RP, Szer J, Weitz IC, Roth A, Hochsmann B, Panse J, Usuki K, Griffin M, Kiladjian JJ, de Castro CM, Nishimori H, Ajayi T, Al-Adhami M, Deschatelets P, Francois C, Grossi F, Risitano AM, Hillmen P. Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial. Lancet Haematol. 2022 Sep;9(9):e648-e659. doi: 10.1016/S2352-3026(22)00210-1. PubMed 36055332 ↗
  • Cella D, Sarda SP, Hsieh R, Fishman J, Hakimi Z, Hoffman K, Al-Adhami M, Nazir J, Cutts K, Lenderking WR. Changes in hemoglobin and clinical outcomes drive improvements in fatigue, quality of life, and physical function in patients with paroxysmal nocturnal hemoglobinuria: post hoc analyses from the phase III PEGASUS study. Ann Hematol. 2022 Sep;101(9):1905-1914. doi: 10.1007/s00277-022-04887-8. Epub 2022 Jul 23. PubMed 35869984 ↗
  • Hakimi Z, Wilson K, McAughey E, Pochopien M, Wojciechowski P, Toumi M, Knight C, Sarda SP, Patel N, Wiseman C, de Castro NP, Nazir J, Kelly RJ. The cost-effectiveness, of pegcetacoplan compared with ravulizumab for the treatment of paroxysmal nocturnal hemoglobinuria, in a UK setting. J Comp Eff Res. 2022 Sep;11(13):969-985. doi: 10.2217/cer-2022-0076. Epub 2022 Jul 7. PubMed 35796199 ↗
  • Bhak RH, Mody-Patel N, Baver SB, Kunzweiler C, Yee CW, Sundaresan S, Swartz N, Duh MS, Krishnan S, Sarda SP. Comparative effectiveness of pegcetacoplan versus ravulizumab in patients with paroxysmal nocturnal hemoglobinuria previously treated with eculizumab: a matching-adjusted indirect comparison. Curr Med Res Opin. 2021 Nov;37(11):1913-1923. doi: 10.1080/03007995.2021.1971182. Epub 2021 Sep 3. PubMed 34445916 ↗
  • Hillmen P, Szer J, Weitz I, Roth A, Hochsmann B, Panse J, Usuki K, Griffin M, Kiladjian JJ, de Castro C, Nishimori H, Tan L, Hamdani M, Deschatelets P, Francois C, Grossi F, Ajayi T, Risitano A, Peffault de Latour R. Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria. N Engl J Med. 2021 Mar 18;384(11):1028-1037. doi: 10.1056/NEJMoa2029073. Erratum In: N Engl J Med. 2024 Mar 14;390(11):1060. doi: 10.1056/NEJMx240003. PubMed 33730455 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2018 to primary completion in Nov 2019, 17 months.

Results were first posted in Mar 2022, 2 years 4 months after primary completion. A results delay was requested in Jul 2020.

Of 35 industry-sponsored phase 3 interventional studies under Hemoglobinuria, Paroxysmal, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 41. This study's 17 months is below that.

Counting every sponsor, half of 35 studies reached it within 23 months; a quarter within 15 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2018
First posted
Apr 18, 2018
StartActual
Jun 14, 2018
Primary completionActual
Nov 14, 2019
CompletionActual
Aug 13, 2020
Results delay requested
Jul 21, 2020
Results first posted
Mar 25, 2022
Last update
Mar 25, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03500549
Responsible party
Sponsor
First posted
Apr 18, 2018
Start date
Jun 14, 2018
Primary completion
Nov 14, 2019
Completion
Aug 13, 2020
Results posted
Mar 25, 2022
Last update
Mar 25, 2022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pegcetacoplan

Start the discussion